stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Debt to equity
Harmony Biosciences Holdings, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.1×, down 0.0× from fiscal 2025 (0.2×). Over the past ten years it has ranged from −8.5× (fiscal 2019) to 2.0× (fiscal 2020); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.2× | (30.85%) |
| FY2024 | 0.3× | (34.38%) |
| FY2023 | 0.4× | (12.87%) |
| FY2022 | 0.5× | (53.79%) |
| FY2021 | 1.0× | (48.50%) |
| FY2020 | 2.0× | — |
| FY2019 | −8.5× | — |
| FY2018 | −1.3× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.1× | (9.73%) |
| Jun 2026 | 0.2× | (11.69%) |
| Mar 2026 | 0.2× | (7.23%) |
| Dec 2025 | 0.2× | (6.79%) |
| 25 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | 0.0× |
| VIR Vir Biotechnology, Inc. compare | 0.0× |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.0× |
| MAZE Maze Therapeutics, Inc. compare | 0.1× |
| HRMY Harmony Biosciences Holdings, Inc. | 0.1× |
| MESO Mesoblast Limited compare | 0.2× |
| SRPT Sarepta Therapeutics, Inc. compare | 0.6× |
| REPL Replimune Group, Inc. compare | 0.6× |
| FTRE Fortrea Holdings Inc. compare | 2.0× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)